Transitional Cell Cancer of the Renal Pelvis and Ureter Completed Phase 2 Trials for Cisplatin (DB00515)

Also known as: Transitional Cell Cancer of Renal Pelvis and Ureter / Transitional Cell Tumor / Transitional cell carcinoma of upper urinary tract (disorder) / Transitional cell cancer of the renal pelvis and ureter NOS / Renal pelvis and ureter transitional cell cancer NOS / Renal pelvis and ureteric cancer NOS transitional cell / Renal pelvis and ureteral cancer transitional cell NOS / Renal pelvis and ureteric cancer transitional cell NOS

IndicationStatusPhase
DBCOND0028512 (Transitional Cell Cancer of the Renal Pelvis and Ureter)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01089088Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)Treatment
NCT00310011Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the UrotheliumTreatment
NCT00080795Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the UrotheliumTreatment
NCT00006111Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary TractTreatment